Veraciti

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Common warts are characterized by their rough, “cauliflower-like” appearance on the surface, making them easily identifiable. Plantar warts are specifically located on the bottom of the foot and are distinguished by tenderness and the disruption of the normal footprint pattern.

Limitations of Use: This drug is not indicated for the treatment of warts located on the face, genitals, or mucous membranes.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm (not hot) water for approximately 5 minutes. After soaking, the area must be dried completely.

The treatment involves applying one drop of the medication at a time to ensure sufficient coverage of each wart. It is essential to allow the application to dry completely before proceeding. This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use is contraindicated in patients with the following conditions:

• Irritated, infected, or reddened skin.

• Moles, birthmarks, or warts with hair growing from them.

• Warts located on the face, genitals, or mucous membranes.

These contraindications are established to prevent potential complications and adverse effects associated with the application of the product in these specific situations.

Warnings and Precautions

For external use only. This product is contraindicated for application on irritated, infected, or reddened skin, as well as on moles, birthmarks, warts with hair growing from them, and warts located on the face, genitals, or mucous membranes.

Healthcare professionals should advise patients to consult a physician prior to use if they have diabetes or experience poor circulation. During application, it is crucial to avoid contact with the eyes. In the event of accidental exposure to the eyes, the affected area should be flushed with water for a minimum of 15 minutes. Additionally, inhalation of vapors should be avoided to prevent respiratory irritation.

Patients should be instructed to discontinue use and seek medical advice if discomfort persists. The product is classified as extremely flammable; therefore, it must be kept away from fire and flame. The tube should be capped tightly and stored at room temperature, away from heat sources.

This product should be kept out of reach of children. In the case of ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center should be made without delay.

Side Effects

Patients should be aware that this product is for external use only. It is contraindicated for use on irritated, infected, or reddened skin, as well as on moles, birthmarks, warts with hair growing from them, and warts located on the face, genitals, or mucous membranes.

Before using this product, patients should consult a healthcare professional if they are diabetic or have poor circulation. During use, it is important to avoid contact with the eyes; in the event of contact, the eyes should be flushed with water for 15 minutes. Additionally, patients should refrain from inhaling vapors associated with the product.

Patients are advised to discontinue use and seek medical advice if discomfort persists. The product is extremely flammable; therefore, it should be kept away from fire and flame. It is recommended to cap the tube tightly and store it at room temperature, away from heat sources.

Furthermore, this product should be kept out of reach of children. In the case of accidental ingestion, immediate medical assistance should be sought or contact with a Poison Control Center should be made.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Veraciti (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Safety during pregnancy has not been established for this medication. It is not recommended for use during pregnancy due to potential risks to the fetus. Healthcare professionals should consider the potential risks and benefits when prescribing this medication to women of childbearing potential. Pregnant patients should be informed of the lack of established safety and the contraindications associated with its use during pregnancy.

Lactation

There are no specific warnings or recommendations regarding the use of Veraciti (salicylic acid gel) in lactating mothers. Additionally, there is no information available about the potential for excretion of salicylic acid in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the drug insert text regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of data necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the event of an overdosage, immediate medical intervention is crucial. If the substance is ingested, it is imperative to seek medical assistance or contact a Poison Control Center without delay.

Healthcare professionals should be aware that prompt action can significantly influence the outcome of an overdosage situation. Symptoms of overdosage may vary depending on the specific substance involved; therefore, a thorough assessment and monitoring of the patient are essential.

Management procedures may include supportive care and symptomatic treatment, tailored to the individual patient's needs. Continuous evaluation and appropriate interventions should be implemented based on the clinical presentation and severity of symptoms.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are provided in the insert for Veraciti (salicylic acid gel).

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children to prevent accidental ingestion. Instruct patients that if the product is swallowed, they should seek medical help or contact a Poison Control Center immediately.

Patients should be informed not to use the product on irritated, infected, or reddened skin, as well as on moles, birthmarks, or warts with hair growing from them. Additionally, it should not be applied to warts located on the face, genitals, or mucous membranes.

Healthcare providers should counsel patients to discontinue use and consult a doctor if discomfort persists after application. It is also important to instruct patients to avoid contact with their eyes while using the product. In the event of contact, they should flush the eye with water for 15 minutes and avoid inhaling any vapors.

Lastly, patients should be encouraged to consult a doctor before using the product if they have diabetes or poor circulation, as these conditions may require special consideration.

Storage and Handling

The product is supplied in a tube that must be capped tightly to maintain integrity. It should be stored at room temperature, away from heat sources. Due to its extremely flammable nature, it is imperative to keep the product away from fire and flame to ensure safety during storage and handling.

Additional Clinical Information

The medication is administered topically, with the recommended application of one drop at a time to adequately cover each wart. The area should be allowed to dry completely, and the procedure may be repeated once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Veraciti, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)